RECENT DEVELOPMENTS ON WALL MATERIALS FOR THE MICROENCAPSULATION OF PROBIOTICS: A REVIEW


Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.

PARP inhibitors target BRCA mutations and defective homologous recombination repair (HRR) for the treatment of epithelial ovarian cancer (EOC).However, the treatment of HRR-proficient EOC with Gift Card PARP inhibitors remains challenging.The objective of this study was to determine whether the combination of triapine (ribonucleotide reductase inhi

read more